INTRODUCTION
Gliomas are one of the most prevalent malignant cancers derived from astrocytes or astroglial cells and can fatally damage the central nervous system [1] . Glioblastoma is
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Keywords: glioma; epigallocatechin-3-gallate; proliferation; apoptosis; invasion III astrocytoma, has a relatively lower invasion rate while diffused and pilocytic astrocytomas are grades II and I respectively, with low invasion rates [2, 3] . However, standard therapies such as surgical resection, chemotherapy, and radiation are ineffective in treating high-grade gliomas.
Furthermore, the survival rate is very low, less than 1 year after conventional treatment [4] .
Green tea is one of the most popular beverages worldwide and is known for its anti-inflammatory, antimutagenic, anti-proliferative, and anti-carcinogenic properties [5] [6] [7] . The most abundant components extracted from green tea is epigallocatechin-3-gallate (EGCG). In contrast to other components, EGCG is a remarkably bioactive compound exhibiting anti-cancer activity. EGCG has been considered a strong chemotherapeutic anticancer drug; however, its molecular mechanisms of action remain unknown.
The laminin receptor with a molecular weight of 67 kDa (67LR) was simultaneously purified in three different laboratories in 1983 [8] [9] [10] . It is frequently overexpressed in tumor cells including gliomas [11, 12] . Studies have also confirmed that tumor invasion and poor prognosis are associated with 67LR overexpression [13] [14] [15] . However, 67LR
is also an effective receptor for EGCG, through which [16] .
It has been reported that matrix metalloproteinases (MMPs) are associated with tumor cell invasion and extracellular matrix degradation, as well as being involved in the proteolytic activation of factors that affect various tumor types [11, 12] . Moreover, MMPs are overexpressed and excessively activated in almost all types of human cancers compared with normal tissues and indicate a poor prognosis [17] [18] [19] .
Studies have shown that apoptosis is induced and cell proliferation is considerably suppressed in the U251 cell line after EGCG treatment [20] . EGCG also inhibits tumor cell growth via the mitogen-activated protein kinase (MAPK) pathway [21] . This was also demonstrated in our study. Extracellular signal-regulated kinases (ERKs), c-Jun NH 2 -terminal kinase (JNK), and P38 are likely involved in EGCG-induced apoptosis and EGCG-inhibited proliferation.
In this study we investigated the effect of EGCG on proliferation, apoptosis, and invasion of glioma cells, and the possible mechnisms. 
MATERIALS AND METHODS

Reagents and Cell Lines
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Total RNA was extracted from U251 cells and then r e v e r s e -t r a n s c r i b e d t o s y n t h e s i z e c D N A u s i n g standard procedures. The primers were as follows:
served as an internal control. The PCR products were electrophoresed on 1% agarose gel, treated with ethidium bromide, and analyzed.
Constructs and Transfection
shRNA-67LR (Allele Biotechnology, San Diego, CA) was transfected to knockdown the expression of 67LR in U251 cells. Random siRNA plasmid, shRNA-67LR-SV (Allele Biotechnology) was used as negative control.
U251 cells were seeded in six-well plates at 1×10 6 / well and allowed to attach for 24 h before transfection. 
Statistical Analysis
Data are presented as mean ± SEM and were analyzed with one-way ANOVA. P <0.05 was considered statistically signifi cant.
RESULTS
EGCG Induces Apoptosis of U251 Cells
Previous studies showed that EGCG induces apoptosis in carcinoma cells without affecting normal cells [22] . Annexin V assays were performed to investigate the apoptosis after U251 cells were treated with EGCG. The apoptotic rate of EGCG-treated U251 cells was higher than that of untreated cells in a dose-dependent manner ( Fig. 1A and 1B ).
Previous research demonstrated that reduction of cancer cell migration occurs through the downregulation of 67LR in human glioma cells in vitro [15] . 67LR has also been identified as an EGCG receptor that regulates an anticancer action in human lung tumor [16] . To verify whether or not EGCG induces glioma cell apoptosis via 67LR, the cells were transfected with shRNA-67LR or shRNA-67LR-SV (negative control) before treatment with EGCG for 48 h. The apoptotic rate of cells transfected with shRNA-67LR was lower than that of shRNA-67LR-SV or without transfection (Fig. 1C) . These fi ndings indicated that EGCG induces glioma cell apoptosis via 67LR.
EGCG Inhibits the Proliferation of U251 Cells
Previous research showed that EGCG suppresses the proliferation of human ovarian cancer cells in vitro [23] .
Here, we found that EGCG (25, 50, 75 , and 100 μg/mL) significantly suppressed the proliferation of glioma cells.
After 72 h of EGCG treatment (100 μg/mL), the maximum suppression of proliferation rate was reached, ~71.52% compared with the 0 μg/mL group. EGCG also decreased cell survival in a dose-dependent manner ( Fig. 2A and B) .
EGCG Affects the Phosphorylation of ERK, JNK, and
P38 in U251 Cells
The MAPK signaling pathway is involved in several physiological processes, including cell proliferation, differentiation, and death. To elucidate the molecular mechanism of EGCG-induced apoptosis and inhibition of proliferation of U251 cells, the levels of phosphorylated P38, ERK1/2, and JNK were evaluated by Western blot.
The results showed that the phosphorylation of MAPKs changed irregularly after treatment with EGCG for 48 h (Fig.   3 ). We found that the activation of P38 and JNK signaling after 72 h EGCG treatment was dose-dependent. The phosphorylation level of ERK1/2 was similarly upregulated at 25 μg/mL EGCG. In contrast, 50, 75, and 100 μg/mL EGCG decreased the level of ERK1/2. No changes were found in total MAPK protein levels.
U251 Cell Invasion Decreases after EGCG Treatment
It has been shown that EGCG can reduce the invasion of human breast cancer cells in vitro [24] . Here, we found that 25 and 50 μg/mL EGCG also decreased the number of cells that invaded the lower membrane compared with untreated U251 cells (Fig. 4B and C) . These results indicated that the invasiveness of U251 cells was weakened after EGCG treatment.
EGCG Inhibits MMP-2 and MMP-9 Expression
We further used RT-PCR to examine the expression of the regulatory genes MMP-2 and MMP-9 that are involved in cell invasion. Their mRNA expression levels were significantly suppressed by EGCG (Fig. 5) . Therefore, EGCG regulated MMP-2 and MMP-9 expression in the U251 glioma cell line. 
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DISCUSSION
Although it is one of the most prevalent brain tumors in the central nervous system, glioma remains poorly treated by chemotherapy and traditional therapies [25] . In this study, we investigated the effect of EGCG on malignant U251 glioma cells and found that it induced apoptosis, inhibited cell proliferation, and reduced the invasion of these aggressive cells. Furthermore, the apoptotic traits induced by EGCG occurred via 67LR, a target of EGCG. However, further studies are needed to determine whether or not 67LR
mediates other benefi cial effects of EGCG.
We investigated the MAPK signaling pathway and found that the phosphorylation of the ERK1/2, JNK, and protein expression in the MAPK pathway has also been reported in lung adenocarcinoma SPC-A-1 cells [26] .
Therefore, the EGCG-induced apoptosis and inhibition of proliferation may be associated with the MAPK signaling cascade in human glioma cells.
To investigate the mechanism by which EGCG reduced cancer cell invasion, we explored MMP-9 and MMP-2 expression after EGCG treatment. An apparent association between tumor aggression and enhanced MMP-9 and MMP-2 levels has been reported in various experimental and clinical studies [27] [28] [29] . For instance, MMP-2 expression is inhibited by Δ
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-tetrahydrocannabinol in glioma cells, resulting in a signifi cant decrease in invasiveness [30] .
In human breast tumor cells, EGCG effectively decreases MMP-9 expression [24] . Here, out data also suggested that MMP-2 and MMP-9 are involved in the EGCG-induced decrease in invasion of human glioma cells.
EGCG is a major polyphenol component of green tea that has gained increasing attention because of its cancer therapeutic and chemopreventive properties. The present study adds to the current knowledge of EGCG, providing evidence that it has anti-tumor activity in human glioma cells and the mechanism was explored. Further studies should be conducted in vivo to test these fi ndings in vitro.
Besides, other chemotherapeutic effects of EGCG against glioma should also be investigated to provide additional information on molecular therapeutic methods in cancer treatment. 
